Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Online ISSN 1827-1634
Caliumi C. 1, Balducci S. 1, Petramala L. 1, Cotesta D. 1, Zinnamosca L. 1, Cianci R. 1, Di Donato D. 1, Vingolo E. M. 3, Fallucca F. 1, Letizia C. 1
1 Department of Clinical Sciences University of Rome La Sapienza, Rome, Italy
2 Department of Internal Medicine University of Rome La Sapienza, Rome, Italy
3 Department of Ophthalmologic Sciences University of Rome La Sapienza, Rome, Italy
Aim. The aim of this study was to investigate whether adrenomedullin (AM) secretion is modified in type 2 diabetic patients with and without retinopathy.
Methods. The study was performed on 92 patients with type 2 diabetes, 65 of whom had uncomplicated diabetes, 27 had retinopathy, and 40 had mild to moderate hypertension. Patients with serum creatinine levels >1.2 mg/dL, were excluded. Circulating AM was assayed using a specific radioimmunoassay.
Results. AM concentrations were significantly higher in type 2 diabetic patients (25±2.1 pg/mL) than in the 31 normal subjects (11±0.8 pg/mL) (P<0.001). Type 2 diabetic patients with retinopathy had significantly greater AM levels (30.8±3.4 pg/mL) than both controls (P<0.001) and type 2 diabetic patients without retinopathy (25.2±2 pg/mL same as previous value) (P<0.001). No statistical difference was found between diabetic patients with preproliferative retinopathy (27.3±4.7 pg/mL) and proliferative retinopathy (24±3.1 pg/mL) (P=0.543). In type 2 diabetic patients, a significant correlation between plasma AM levels and HbA1c values (r=0.467; P<0.01) was found.
Conclusion. Our findings indicate that circulating AM is increased in type 2 diabetic patients and that increase correlates with poor glucose metabolic control and presence of retinopathy.